MarketPulse — Real-Time Financial News & Market Analysis

Latest News

15,862 articles
Fri, Mar 13
The Motley FoolThe Motley Fool··Jonathan Ponciano

Deerfield Doubles Down on Vera Therapeutics as Kidney Drug Nears FDA Decision

Deerfield Management increases Vera Therapeutics stake to $205.58M as kidney drug atacicept approaches July 7 FDA decision. Stock up 50% annually.
VERAFDA approvalbiotech
Investing.comInvesting.com··Jesse Cohen

Energy Rally Creates Opportunity in Undervalued Mid-Caps as Oil Nears $100

Three undervalued mid-cap energy stocks—Talos Energy, Patterson-UTI, and Northern Oil & Gas—offer significant upside as WTI approaches $95 amid Middle East tensions.
TALOPTENNOGenergy stocksoil prices
The Motley FoolThe Motley Fool··Neil Patel

Uber CEO Reframes AV Threat as Multitrillion-Dollar Opportunity

Uber CEO Khosrowshahi addresses autonomous vehicle concerns, positioning AVs as growth driver rather than threat. Plans 15-city AV rollout by end-2026.
GOOGGOOGLUBERTSLAautonomous vehiclescompetitive advantage
The Motley FoolThe Motley Fool··Leo Sun

Nvidia's $177M Applied Digital Exit: Portfolio Shift or Warning Sign?

Nvidia sold its entire $177M stake in Applied Digital in Q4 2025. Despite the exit, the AI infrastructure company's $16B contracted revenue and sector growth remain intact, though customer concentration risk persists.
NVDACRWVEQIXAPLDDLR+3data centerscloud computing
The Motley FoolThe Motley Fool··Jeremy Bowman

Adobe's CEO Exodus: Market Overreaction or Warning Sign for 2026?

Adobe CEO Shantanu Narayen steps down after 18 years; stock falls 5% despite beating Q1 earnings with $6.4B revenue. Valuation now at 12x P/E.
ADBEFIGstock valuationAI disruption
The Motley FoolThe Motley Fool··Jonathan Ponciano

Deerfield Doubles Down on Celcuity With $170M Stake as Stock Soars 1,040%

Deerfield Management increased its Celcuity stake by $80.6M in Q4, bringing total position to $170.95M. Stock surged 1,040% amid FDA review of breast cancer drug gedatolisib.
CELCFDA approvalbiotech
BenzingaBenzinga··Nabaparna Bhattacharya

SOLAI Stock Tumbles Despite $3.07 Takeover Bid Above Net Asset Value

SOLAI shares decline 5.06% despite $3.07-per-share acquisition offer from Chaince Digital, representing 110% premium to net asset value amid deal completion uncertainty.
SLAItechnical analysisearnings report
The Motley FoolThe Motley Fool··Anders Bylund

KinderCare Stock Crashes 39% Despite Beating Earnings on Bleak 2026 Outlook

KinderCare Learning Companies stock plunged 39% after beating Q4 earnings but issuing weak 2026 guidance, citing operational challenges and macroeconomic headwinds.
KLCearnings missstock plunge
The Motley FoolThe Motley Fool··Daniel Sparks

Dollar General Stock Falls on Growth Slowdown Fears Despite Strong Q4 Beat

$DG slides 6% despite Q4 beat, as fiscal 2026 guidance projects same-store sales growth to decelerate sharply to 2.2%-2.7%.
DGvaluationearnings beat
The Motley FoolThe Motley Fool··Rich Smith

Angel Studios Stock Plunges 11.2% on Wider-Than-Expected Q4 Loss

$ANGX fell 11.2% after beating revenue targets but missing earnings expectations. Despite 254% YoY revenue growth, losses doubled.
DISANGXstock declineprofitability
The Motley FoolThe Motley Fool··Daniel Miller

U.S. EV Market Hits First Decline in Decade as Tax Credit Expiration Stalls Growth

U.S. EV registrations fell 0.4% in 2025, marking the first decline in ten years. December plunged 48% after federal tax credits expired, though Tesla maintains dominance.
TSLAFFpBFpCFpD+1electric vehiclesmarket share
The Motley FoolThe Motley Fool··Jonathan Ponciano

Biotech Darling Praxis Stock Soars 700% as Major Fund Doubles Down With $266M Bet

Deerfield Management boosts $PRAX stake to $266M as biotech stock surges 685% annually. Company eyes $20B+ pipeline revenue potential with two FDA applications pending.
PRAXFDA approvalbiotech
GlobeNewswire Inc.GlobeNewswire Inc.··Marketsandmarkets™

Propylene Oxide Market Poised for $18.88B Expansion as EV Boom Drives Lightweight Material Demand

Propylene oxide market expected to reach $18.88B by 2030 at 4.9% CAGR, driven by EV lightweighting and polyurethane foam demand in construction.
LYBSHELDOWAsia-Pacificelectric vehicles
GlobeNewswire Inc.GlobeNewswire Inc.··Faruqi & Faruqi, Llp

FBRT Faces Securities Class Action Over Missed Earnings, Dividend Claims

Franklin BSP Realty Trust faces shareholder lawsuit alleging false statements about earnings and dividends after Q4 2025 results missed consensus by 27% on revenue.
FBRTFBRTpEstock declineearnings miss
GlobeNewswire Inc.GlobeNewswire Inc.··Graniteshares Inc.

GraniteShares Boosts Weekly Payouts on YieldBOOST ETFs Amid Income Strategy Shift

GraniteShares announced weekly distributions for YBST and YBTY ETFs, with YBTY yielding 72.31% and YBST at 62.37%, using put-writing strategies.
YBTYYBSTETFincome generation
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Crédit Agricole Issues €228.5M Senior Bond While Expanding Ukraine Operations

Crédit Agricole issues €228.5M senior bonds at 3.40% maturing 2036 while its Ukraine subsidiary acquires Bank Lviv, strengthening regional presence and capital position.
CRARYacquisitionUkraine
BenzingaBenzinga··Vandana Singh

Insulet Plunges to 52-Week Low After Omnipod 5 Safety Recall

Insulet stock hits 52-week low after voluntary Omnipod 5 recall due to insulin delivery tubing defect. 18 serious adverse events reported.
XHEPODDBCSMTMATtechnical analysis52-week low
Investing.comInvesting.com··Sam Quirke

Chevron Surges 30% on Oil Rally, But Geopolitical Gains May Be Fleeting

Chevron surges 30% in 2026 on oil rally amid Middle East tensions, but fading momentum and potential SPR releases threaten sustainability of gains.
CVXtechnical analysisenergy stocks
BenzingaBenzinga··Globe Newswire

NewtekOne Maintains Dividend Payouts on Common and Preferred Shares

NewtekOne declares $0.19 common dividend and $0.53125 preferred dividend, payable April 2026 to shareholders of record March 24, 2026.
NEWTNEWTGNEWTHNEWTINEWTO+1quarterly dividendshareholder returns
The Motley FoolThe Motley Fool··Jonathan Ponciano

Biotech Darling $PRAX Soars 685% as $80.5M Investment Bets on Dual FDA Filings

$PRAX surges 685% annually, securing $80.5M from Driehaus Capital. Two FDA applications pending for neurological therapies with potential $20B+ revenue.
TSMPRAXGHbiotechinstitutional investment